What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.

Bookmark this %label%

Multiple strategies have been used to evaluate the minimal important change (MIC) of the Eczema Area and Severity Index (EASI) and Scoring Atopic Dermatitis (SCORAD). The meaningfulness of these MICs […]

» Read more

What’s new in atopic eczema? An analysis of systematic reviews published in 2018. Part 1: prevention and topical therapies.

Bookmark this %label%

This review is part of a series of annual updates that summarize the evidence base for atopic eczema (AE). The aim is to provide a succinct guide for clinicians on […]

» Read more

Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis.

Bookmark this %label%

Dupilumab, the first biological drug to be approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults has shown good efficacy and safety in clinical trials.To evaluate […]

» Read more

What’s new in atopic eczema? An analysis of systematic reviews published in 2018. Part 2: systemic therapies.

Bookmark this %label%

This review forms part of an annual update series on atopic eczema (AE), where systematic reviews (SRs) are gathered and appraised to provide a summary of key recent research findings. […]

» Read more

Views and experiences of managing eczema: systematic review and thematic synthesis of qualitative studies.

Bookmark this %label%

The number of qualitative studies on eczema has increased rapidly in recent years. Systematically reviewing these can provide greater understandings of people’s perceptions of eczema and eczema treatments.We sought to […]

» Read more

Patient-Reported Outcomes for Measuring Sleep Disturbance in Pediatric Atopic Dermatitis: cross sectional study of PROMIS Pediatric Sleep Measures and Actigraphy.

Bookmark this %label%

Most children with atopic dermatitis(AD) suffer from sleep disturbance, but reliable and valid assessment tools are lacking.To test PROMIS (Patient Reported Outcomes Measurement Information System) sleep measures in pediatric AD […]

» Read more

Efficacy and Patient-Reported Outcomes from a Phase IIb, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Adolescents and Adults with Atopic Dermatitis.

Bookmark this %label%

Tapinarof is a topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) under investigation for atopic dermatitis (AD) and psoriasis treatment.Phase IIb, double-blind, vehicle-controlled study randomized adolescents and adults with AD […]

» Read more

Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.

Bookmark this %label%

Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking.To investigate patient characteristics, treatment aspects, effectiveness and safety of up to 84 weeks of dupilumab treatment.An observational […]

» Read more

Initial validation of the product of the signs global assessment and body surface area (SGAxBSA) in atopic dermatitis.

Bookmark this %label%

Current valid instruments that measure the signs of AD in clinical trials may not be suitable for clinical practice due to their complexity. The product of a clinician-derived 5-point signs […]

» Read more

Measurement properties of the Rajka-Langeland severity score in children and adults with atopic dermatitis.

Bookmark this %label%

Multiple atopic dermatitis (AD) severity scales exist, with no gold-standard for use in clinical practice.Determine the measurement properties of the Rajka-Langeland score and compare with other clinician-reported outcomes in adults […]

» Read more

Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature.

Bookmark this %label%

Atopic dermatitis (AD) is a chronic relapsing eczematous dermatitis typically affecting young patients in a percentage from 15 to 20%; although it typically affects young people and adults, recent papers […]

» Read more

Partner bereavement and risk of chronic urticaria, alopecia areata and vitiligo: cohort studies in the United Kingdom and Denmark.

Bookmark this %label%

The pathogeneses of skin diseases are not fully understood. Psychological stress has been proposed to be associated with skin diseases, but the epidemiological evidence is limited [1, 2]. We have […]

» Read more

Spectrum of skin diseases in Amerindian villages of the Upper Oyapock, French Guiana.

Bookmark this %label%

Due to their genetic characteristics, their isolation in rainforest areas, and their traditional way of life, Amerindian populations are likely to suffer from a specific spectrum of dermatoses. However, there are few available […]

» Read more

The European TREatment of ATopic eczema Taskforce (TREAT) Survey; prescribing practices in Europe for phototherapy and systemic therapy in moderate-to-severe adult atopic eczema patients.

Bookmark this %label%

For many years dermatologists have had access to few therapies for patients with moderate-to-severe atopic eczema (AE). New promising therapies are entering the market but conventional phototherapies and systemic therapies […]

» Read more

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.

Bookmark this %label%

Previous studies showed the potential effectiveness of delgocitinib ointment, a novel topical Janus kinase inhibitor, in atopic dermatitis (AD).This study aimed to evaluate the efficacy and safety of delgocitinib 0.5% ointment.In […]

» Read more

Validation of Patient-Reported Outcomes Information System Sleep Disturbance and Sleep-Related Impairment in Adults With Atopic Dermatitis.

Bookmark this %label%

Sleep disturbances (SD) are common in adults with atopic dermatitis (AD). Patient-Reported Outcomes Measurement Information System (PROMIS™) SD and Sleep-Related Impairment (SRI) are validated questionnaires to assess sleep in adults. […]

» Read more

Product of Investigator Global Assessment and body surface area (IGAxBSA): a practice-friendly alternative to the Eczema Area and Severity Index (EASI) to assess atopic dermatitis severity in children.

Bookmark this %label%

Accurately documenting pediatric atopic dermatitis (AD) severity is important, but research tools, such as Eczema Area and Severity Index (EASI), are too time-consuming for clinical settings. Product of the Physician […]

» Read more
1 2 3